SASSARI, Italy & PRINCETON, N.J.--()--Dr. Franco Lori, Chief Executive Officer of ViroStatics, will present a Company Overview during the BIO-Europe Spring 2009 conference at 09:30 AM on Wednesday, 18 March, 2009 in Milano, Italy. Dr Lori will discuss the Company's recent advancements in drug discovery and development in the areas of HIV/AIDS and cancer as well as the plans to commercialize ViroStatics’ proprietary biomarker assays.
Specifically, Dr. Lori will review the company’s successes in discovering and developing a new class of drugs known as Anti-Viral Hyper-Activation Limiting Therapeutics (AV-HALT) that have been designed not only to suppress viral replication but also to preserve the immune system from chronic damage. ViroStatics has recently completed a Phase II multi-national clinical trial of its lead product, VS411- a fixed combination of virostatic drugs believed to be the first in the new AV-HALT class of drugs. The Company’s progress in developing a unique series of biomarker assays to quantify the functionality of the immune system’s memory T-cells against HIV as well as other viral and bacterial pathogens will be highlighted. In addition, ViroStatics has recently acquired an extensive library of potential AV-HALT compounds, a number of which also may have value as anti-cancer agents. Lastly, Dr. Lori will discuss potential partnering opportunities with the companies attending the conference in the areas of antivirals, anti-cancer agents, and novel diagnostic assays.
ViroStatics srl, an Italian pharmaceutical company with operations in Sassari and Pavia, Italy and Princeton, NJ, USA is committed to discovering and developing novel therapeutics to address significant medical needs in HIV/AIDS, chronic infections, cancer, and related fields. The company’s lead product, VS411, the first fixed-dose combination of two drugs from a new class known as Anti-Viral Hyper-Activation Limiting Therapeutics (AV-HALT) that not only decrease HIV replication but also protect and conserve the immune system, has recently completed a multinational Phase II clinical trial. ViroStatics has also developed novel biomarker assays and a proprietary screening methodology to rapidly and efficiently identify AV-HALT agents with potential to inhibit viral replication and control the over-stimulation of the immune system that is believed to drive the progression of HIV to AIDS. ViroStatics is committed to expanding its pipeline and product portfolio by in-licensing early- and late-stage compounds and exploring co-development opportunities that fit the Company's expertise in specialty pharmaceuticals.